Simulations Plus, Inc. (NASDAQ:SLP) is expected to pay $0.05 on Nov 17, 2016. The indicated annual dividend is $0.20. Shareholders owning the stock before Nov 8, 2016 will be eligible to receive the payout. Based on Simulations Plus, Inc.’s current price of $8.65, the dividend is 0.58%. This dividend’s record date is Nov 10, 2016 and the announcement date is Oct 31, 2016. The stock closed at $8.65 during the last session. It is down 2.73% since April 5, 2016 and is uptrending. It has outperformed by 0.78% the S&P500.
Simulations Plus, Inc. develops and produces software for use in pharmaceutical research and for education, and provides consulting and contract research services to the pharmaceutical industry. The company has a market cap of $149.26 million. The Firm offers five software products for pharmaceutical research. It has a 32 P/E ratio. ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Predictor is a computer program that takes molecular structures as inputs and predicts over 140 different properties for them at the rate of about 200,000 compounds per hour.
Insitutional Activity: The institutional sentiment decreased to 0.72 in 2016 Q2. Its down 0.97, from 1.69 in 2016Q1. The ratio worsened, as 12 funds sold all Simulations Plus, Inc. shares owned while 13 reduced positions. 3 funds bought stakes while 15 increased positions. They now own 4.10 million shares or 10.61% less from 4.59 million shares in 2016Q1.
Gsa Cap Partners Llp accumulated 0.04% or 104,425 shares. The California-based Menta Cap Limited Liability has invested 0.01% in Simulations Plus, Inc. (NASDAQ:SLP). The Illinois-based North Star Mngmt has invested 0.17% in Simulations Plus, Inc. (NASDAQ:SLP). Deutsche Savings Bank Ag holds 38,472 shares or 0% of its portfolio. Ranger Mgmt Limited Partnership holds 0.04% of its portfolio in Simulations Plus, Inc. (NASDAQ:SLP) for 95,830 shares. The New York-based Tower Limited Com (Trc) has invested 0.01% in Simulations Plus, Inc. (NASDAQ:SLP). Crawford Counsel has 280,178 shares for 0.08% of their US portfolio. Millennium Lc holds 0% of its portfolio in Simulations Plus, Inc. (NASDAQ:SLP) for 21,976 shares. Renaissance Lc accumulated 532,200 shares or 0.01% of the stock. The California-based California Pub Employees Retirement Systems has invested 0% in Simulations Plus, Inc. (NASDAQ:SLP). Springbok Capital Mgmt Lc holds 0% or 2,900 shares in its portfolio. Connors Investor Service Inc has 26,957 shares for 0.04% of their US portfolio. Dimensional Fund Advisors L P reported 339,427 shares or 0% of all its holdings. Rice Hall James And Assoc Limited Liability has 65,810 shares for 0.03% of their US portfolio. Acadian Asset Mgmt Limited Liability Co accumulated 22,055 shares or 0% of the stock.
More recent Simulations Plus, Inc. (NASDAQ:SLP) news were published by: Quotes.Wsj.com which released: “News Simulations Plus Inc.SLP” on February 11, 2011. Also Seekingalpha.com published the news titled: “Shorting Simulations Plus Is Silly” on February 23, 2016. Seekingalpha.com‘s news article titled: “Simulations Plus, Inc. Passes Its Checkup (SLP)” with publication date: January 29, 2015 was also an interesting one.
SLP Company Profile
Simulations Plus, Inc., incorporated on July 17, 1996, is a well-known provider of simulation and modeling software for pharmaceutical discovery and development. The Firm offers its services and products through two business units, including Simulations Plus, Inc. and Cognigen Corporation. The Firm also provides consulting services ranging from early drug discovery through preclinical and clinical trial data analysis and reporting to regulatory agencies. The Firm offers over seven software products for pharmaceutical research and development, including three simulation programs that provide time-dependent results on solving various sets of differential equations: GastroPlus, DDDPlus and MembranePlus; three programs that are based on predicting and analyzing static properties of chemicals: ADMET Predictor, MedChem Designer and MedChem Studio, which is a combination of ADMET Predictor, MedChem Designer and MedChem Studio is called its ADMET Design Suite, and a program that supports data analysis and reporting through its secure cloud called KIWI. The Company’s PKPlus software product is used for non-compartmental pharmacokinetic analysis and reporting. The Firm distributes its products and offers its services in North America, South America, Europe, Japan, Australia, New Zealand, India, Singapore and the People’s Republic of China.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.